Oligodendrogliomas
Authors:
- Agustí AlentornAAAgustí Alentorn
- Marc SansonMSMarc Sanson
- Ahmed IdbaihAhmed Idbaih
- 1 November 2012
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 24 (6) , 687-693
Abstract
Since the discovery, in 1994, of recurrent codeletion of chromosome regions 1p36/19q13 in oligodendrogliomas, genetics has accomplished significant advances improving our knowledge in biology of this tumor type and our clinical management of oligodendroglioma patients. Indeed, 1p36/19q13 has been shown successively to predict increased chemosensitivity and better prognosis, to be associated with frontal location in brain and classic oligodendroglioma morphology, to be mutually exclusive with high-level gene amplification, to be actually whole chromosome arms 1p/19q codeletion, to mediate a t(1;19)(q10;p10) and to be associated with IDH mutations. More recently, pivotal studies, using high-throughput approaches, have provided significant novel insights in the molecular oncogenesis of oligodendrogliomas. Capicua homolog (Drosophila) (CIC) and Far Upstream element Binding Protein 1 (FUBP1) have been shown to be frequently mutated in 70 and 40% of 1p/19q codeleted oligodendrogliomas, respectively. The biological and clinical significance of these mutations remains unsettled. Additional recent studies have also demonstrated that 1p/19q codeleted oligodendrogliomas exhibit a proneural transcriptomic profile including overexpression of internexin alpha, a neuronal intermediate filament. Finally, 1p/19q codeleted and IDH-mutated tumors have been shown to be hypermethylated, suggesting a strong link between these both molecular alterations detected in the subgroup of oligodendrogliomas with better prognosis. Next-generation molecular biology technologies have recently identified recurrent CIC and FUBP1 point mutations in 1p/19q codeleted and IDH-mutated oligodendrogliomas. Their clinical and biological values are under investigation.Keywords
This publication has 40 references indexed in Scilit:
- Anaplastic oligodendroglial tumorsHandbook of Clinical Neurology, 2012
- Update on molecular findings, management and outcome in low-grade gliomasNature Reviews Neurology, 2010
- Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951Journal of Neuro-Oncology, 2010
- Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951Neuro-Oncology, 2009
- Chromosome 9p and 10q losses predict unfavorable outcome in low-grade gliomasNeuro-Oncology, 2009
- IDH1andIDH2Mutations in GliomasNew England Journal of Medicine, 2009
- NOTCH2 Is Neither Rearranged nor Mutated in t(1;19) Positive OligodendrogliomasPLOS ONE, 2009
- An Integrated Genomic Analysis of Human Glioblastoma MultiformeScience, 2008
- Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III TrialJournal of Clinical Oncology, 2006
- Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402Journal of Clinical Oncology, 2006